Literature DB >> 9379018

B cell antigen receptor-evoked calcium influx is enhanced in CD22-deficient B cell lines.

M J Nadler1, P A McLean, B G Neel, H H Wortis.   

Abstract

CD22 is a B cell membrane glycoprotein that, upon Ag receptor engagement, becomes rapidly tyrosyl phosphorylated and associates with several signaling molecules including Lyn, Syk, PLCgamma1, and the protein-tyrosine phosphatase, SHP-1. Two allelic forms of murine CD22 exist: CD22.1 is expressed in strains such as NZB and DBA/2, whereas CD22.2 is expressed in BALB/c and most other strains. WEHI-231 cells, which derive from a (BALB/c x NZB)F1 mouse, express one copy of each allele. Previous studies have proposed both positive and negative functions for CD22. We explored the role of CD22 in surface IgM Ag receptor signal transduction by examining signaling in three clonally independent WEHI-231 variants that have lost expression of the CD22.2 allele. This experimental design allowed us to assess the signaling functions of CD22 independent of its developmental role. These variants, which exhibit a 50% reduction of total surface CD22, are hyper-responsive to Ag receptor stimulation: several cellular proteins are hyperphosphorylated on tyrosyl residues and surface IgM-mediated calcium flux is markedly increased. Interestingly, the increased calcium response observed in CD22-deficient cells is due largely to enhanced calcium influx. Reconstitution of CD22 expression reduces these changes. The SHP-1/CD22 association is reduced in CD22-deficient cell lines and is restored by re-expression of CD22. Our results demonstrate that CD22 is a cell autonomous negative regulator of B cell Ag receptor signaling, and suggest that it regulates calcium entry via a mechanism downstream from or independent of calcium release from intracellular stores.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9379018

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Normal B-1a cell development requires B cell-intrinsic NFATc1 activity.

Authors:  Robert Berland; Henry H Wortis
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-31       Impact factor: 11.205

2.  The paired Ig-like receptor PIR-B is an inhibitory receptor that recruits the protein-tyrosine phosphatase SHP-1.

Authors:  M Bléry; H Kubagawa; C C Chen; F Vély; M D Cooper; E Vivier
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

Review 3.  Treatment of systemic lupus erythematosus with epratuzumab.

Authors:  Pawel Traczewski; Lidia Rudnicka
Journal:  Br J Clin Pharmacol       Date:  2011-02       Impact factor: 4.335

4.  Estrogen alters thresholds for B cell apoptosis and activation.

Authors:  Christine M Grimaldi; James Cleary; A Selma Dagtas; Dariush Moussai; Betty Diamond
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

5.  CD19 signaling is impaired in murine peritoneal and splenic B-1 B lymphocytes.

Authors:  Trivikram Dasu; Vishal Sindhava; Stephen H Clarke; Subbarao Bondada
Journal:  Mol Immunol       Date:  2009-06-21       Impact factor: 4.407

6.  Role of initial protein phosphorylation events and localized release-activated calcium influx in B cell antigen receptor signaling.

Authors:  Taras Lyubchenko; J Paul Nielsen; Sara M Miller; Ganna A Liubchenko; V Michael Holers
Journal:  J Leukoc Biol       Date:  2008-11-21       Impact factor: 4.962

7.  Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus.

Authors:  Thomas Dörner; Joerg Kaufmann; William A Wegener; Nick Teoh; David M Goldenberg; Gerd R Burmester
Journal:  Arthritis Res Ther       Date:  2006-04-21       Impact factor: 5.156

8.  Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies.

Authors:  T L O'Keefe; G T Williams; F D Batista; M S Neuberger
Journal:  J Exp Med       Date:  1999-04-19       Impact factor: 14.307

9.  Sialic acid binding domains of CD22 are required for negative regulation of B cell receptor signaling.

Authors:  Lei Jin; Paul A McLean; Benjamin G Neel; Henry H Wortis
Journal:  J Exp Med       Date:  2002-05-06       Impact factor: 14.307

10.  Group B Streptococcus engages an inhibitory Siglec through sialic acid mimicry to blunt innate immune and inflammatory responses in vivo.

Authors:  Yung-Chi Chang; Joshua Olson; Federico C Beasley; Christine Tung; Jiquan Zhang; Paul R Crocker; Ajit Varki; Victor Nizet
Journal:  PLoS Pathog       Date:  2014-01-02       Impact factor: 6.823

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.